Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 19/20 | 0.43 |
| ▸ | KRAS | P01116 | 1/20 | 0.38 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17076642 | 0.82 | AAK1 (0.51) | AAK1KRASSOS1 | |
| SCHEMBL21455348 | 0.82 | AAK1 (0.51) | AAK1KRASSOS1 | |
| SCHEMBL20868007 | 0.82 | AAK1 (0.51) | AAK1KRASSOS1 | |
| SCHEMBL21455062 | 0.82 | AAK1 (0.42) | AAK1KRASSOS1 | |
| SCHEMBL16437282 | 0.82 | AAK1 (0.46) | AAK1KRASSOS1 | |
| SCHEMBL22387666 | 0.80 | AAK1 (0.43) | AAK1 | |
| SCHEMBL22270895 | 0.80 | AAK1 (0.42) | AAK1 | |
| SCHEMBL24565301 | 0.79 | AR (0.45) | — | |
| SCHEMBL14647203 | 0.79 | CHRM2 (0.38) | — | |
| SCHEMBL20867824 | 0.79 | AAK1 (0.41) | AAK1KRASSOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3553064-B1 | COMPOUND CONTAINING TRICYCLIC HETEROARYL GROUP | HANGZHOU INNOGATE PHARMA CO LTD (CN) | 2023-06-07 | — | — | EP | disclosed |
| EP-3553064-A1 | COMPOUND CONTAINING TRICYCLIC HETEROARYL GROUP | Hangzhou Innogate Pharma Co., Ltd. (CN) | 2019-10-16 | — | — | EP | disclosed |
| EP-3027601-B1 | SYK INHIBITORS | GILEAD SCIENCES INC (US) | 2017-10-25 | — | — | EP | disclosed |
| US-20160368918-A1 | SYK INHIBITORS | Kronos Bio, Inc. | 2016-12-22 | — | — | US | disclosed |
| US-9376441-B2 | Substituted pyrrolidines as SYK inhibitors | GILEAD SCIENCES, INC. (US) | 2016-06-28 | — | — | US | disclosed |
| US-20150038488-A1 | SYK INHIBITORS | Kronos Bio, Inc. | 2015-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150038488-A1 | SYK INHIBITORS | SYK, BTK, LYN | AAK1 1261/4885KRAS 386/4885SOS1 2293/4885 |
| US-20160368918-A1 | SYK INHIBITORS | SYK, BTK, LYN | AAK1 1171/4885KRAS 380/4885SOS1 2122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.